In ICU or negative pressure ward, millions of airborne particles (or virus) are floating in the air. Neither N95 (95% capture rate, fit-test performed before use) nor other brand's PAPR (99.97% filtration efficiency) can protect HCWs from SARS-Cov-2 attacks. Only 100% filtration efficiency PAPR can do, that is our device.
Our PAPR is the first revolutionary respirator which can be used by children, the elderly, pregnant and vulnerable group of people who are weak in health condition, this group of people can not use N95 due to its high pressure.
We started first generation PAPR project in 2013. Shipped 3,700 units to China market in 2015. We are looking for seed fund to proceed our second generation PAPR which is light-weight, low cost, and high quality. The technology was ready in 2015. Hardware is mini51 CPU, Keil C program. The problem we have now is we need seed fund to get into mass production, and it may take another 5 months. All R&D problems were solved before 2015.
NIOSH 42CFR84 standards